Bicalutamide for advanced prostate cancer: The natural versus treated history of disease Academic Article uri icon

Overview

MeSH Major

  • Androgen Antagonists
  • Androgens
  • Anilides
  • Antineoplastic Agents, Hormonal
  • Neoplasms, Hormone-Dependent
  • Prostatic Neoplasms

abstract

  • Classifying patient tumors on the basis of prior hormone exposure permits a more precise estimate of the potential benefit of a specific hormone therapy for the individual patient. The precision is further increased by reporting the effects of a drug on each parameter of disease independently. The difference in outcomes for patients with androgen-independent progression suggests that the specific hormone therapy administered and the response to that therapy can influence the biology of the relapsing tumor and the sensitivity to subsequent therapies. The sensitivity to bicalutamide after progression on flutamide deserves further study.

publication date

  • August 1997

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 9256137

Additional Document Info

start page

  • 2928

end page

  • 38

volume

  • 15

number

  • 8